profit from every $100 of sales.
$0$100
Assembly Biosciences
$21.79+6.71% today
-30.2% in 1 year
1-year low $19.511-year high $38.50
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Assembly Biosciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $72.3 million in 2025, with -$6.12 million of profit last year.
SalesProfit
Assembly Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Assembly Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Assembly Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 7 | 29 | 72 | |
| – | – | – | – | |
| -94 | -65 | -45 | -12 | |
| -94 | -64 | -45 | -12 | |
| -93 | -61 | -40 | -6 | |
| -23.04 | -13.38 | -6.69 | -0.55 | |
| – | – | – | – | |
| – | -902.5% | -159.3% | -16.8% | |
| – | -854.8% | -140.9% | -8.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 102 | 137 | 119 | 258 |
| Cash | 52 | 20 | 38 | 58 |
| Total debt | 3 | 2 | 3 | 3 |
| Total liabilities | 19 | 96 | 86 | 51 |
| 83 | 41 | 33 | 207 | |
| 4 | 5 | 6 | 11 | |
| -86.3% | -117.6% | -98.4% | -4.6% | |
| -112.6% | -149.0% | -120.4% | -3.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -84 | 23 | -51 | -41 | |
| 0 | 0 | 0 | 0 | |
| -85 | 22 | -51 | -41 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 5 | 3 | 5 |
Valuation
- –
- –
- –
- 2.3×
- 6.1×
- –
- –
- -9.3%
- -1.4%
- 0.0%
Profitability
- 77.2%
- -16.8%
- -8.5%
- -16.5%
- -6.7%
- -87.2%
- -4.2%
- -2.7%
- -6.8%
- 91.2%
Growth
- +217.7%
- –
- +19.5%
- –
- +32.8%
Financial health
- -4.7×
- 0.01
- 1.1%
- –
- 6.65
- 6.65
- 0.30
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 30%of 948
Bottom 13%of 871
Top 1%of 868
Bottom 12%of 985
What analysts expect
- Average price target
- $40.00
- Range
- $40.00 – $40.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.54 | -0.73 | +26.0% |
| Mar 19, 2026 | 2.48 | -0.51 | +586.3% |
| Nov 10, 2025 | -0.72 | -0.50 | −44.0% |
| Aug 6, 2025 | -1.33 | -0.65 | −103.6% |
| May 8, 2025 | -1.17 | -2.01 | +41.8% |
| Mar 20, 2025 | -1.57 | -1.75 | +10.3% |
| Nov 7, 2024 | -1.51 | -2.02 | +25.2% |
| Aug 8, 2024 | -1.98 | -2.96 | +33.1% |
News
In photos: Key takeaways from day one of the UN General AssemblyCNBC · Sep 23, 2026Trump to meet with NYC Mayor Zohran Mamdani on Monday ahead of UN General AssemblyCNBC · Sep 20, 2026The newest story we have is from Sep 23, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
50No pass
Philip Fisher
42No pass
Peter Lynch
50No pass
Joel Greenblatt
0No pass
Charlie Munger
34No pass
Terry Smith
34No pass
Questions about Assembly Biosciences
Is Assembly Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Assembly Biosciences AI analysis
What does Assembly Biosciences do?
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. It is in Biotechnology.
Does Assembly Biosciences pay a dividend?
No. Assembly Biosciences does not pay a dividend at the moment.
Is Assembly Biosciences stock halal?
No. Assembly Biosciences does not pass our halal screen: its cash and confirmed interest-bearing investments are 56% of its market value, at or above the 33% limit. How we check
How has Assembly Biosciences stock done over the past year?
Down 30.2% over the past twelve months, to $21.79. It traded between $19.51 and $38.50 and is 43.4% below its high.
Who are Assembly Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Assembly Biosciences's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.